Omalizumab is effective in nonautoimmune urticaria

Journal of Allergy and Clinical Immunology

Volumn 127, Issue 5, 2011, Pages 1300-1302

  Ferrer, Marta ^a   Gamboa, Pedro ^b   Sanz, Maria L ^a   Goikoetxea, Maria Jose ^a   Cabrera Freitag, Paula ^a   Javaloyes, Gracia ^a   Berroa, Felicia ^a   Kaplan, Allen P ^c  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD63 ANTIGEN; CETIRIZINE; CORTICOSTEROID; CYCLOSPORIN; DEFLAZACORT; DOXEPIN; FEXOFENADINE; HISTAMINE; HYDROXYZINE; LEVOCETIRIZINE; METHYLPREDNISOLONE; MONTELUKAST; OMALIZUMAB; OMEPRAZOLE; PREDNISONE; RANITIDINE;

ADULT; ANTIGEN EXPRESSION; BASOPHIL; CHRONIC URTICARIA; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HISTAMINE RELEASE; HUMAN; HUMAN CELL; LETTER; MALE; PRIORITY JOURNAL; REMISSION;

EID: 79955575746     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.12.1085     Document Type: Article

References (9)

1. P.M. Gamboa, M.L. Sanz, M.R. Caballero, I. Antepara, I. Urrutia, and I. Jauregui Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients Allergy 58 2003 312 317 (Pubitemid 36566749)
2. E. Luquin, A.P. Kaplan, and M. Ferrer Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli Clin Exp Allergy 35 2005 456 460 (Pubitemid 40577237)
3. M.L. Sanz, P.M. Gamboa, I. Antepara, C. Uasuf, L. Vila, and C. Garcia-Aviles Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics Clin Exp Allergy 32 2002 277 286 (Pubitemid 34429608)
4. T. Zuberbier, R. Asero, C. Bindslev-Jensen, G. Walter Canonica, M.K. Church, and A. Giménez-Arnau EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria Allergy 64 2009 1417 1426
5. A. Mlynek, A. Zalewska-Janowska, P. Martus, P. Staubach, T. Zuberbier, and M. Maurer How to assess disease activity in patients with chronic urticaria? Allergy 63 2008 777 780 (Pubitemid 351591864)
6. L.A. Beck, G.V. Marcotte, D. MacGlashan, A. Togias, and S. Saini Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function J Allergy Clin Immunol 114 2004 527 530 (Pubitemid 39194924)
7. J.M. Oliver, C.A. Tarleton, L. Gilmartin, T. Archibeque, C.R. Qualls, and L. Diehl Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy Int Arch Allergy Immunol 151 2010 275 284
8. D.W. MacGlashan Jr., B.S. Bochner, D.C. Adelman, P.M. Jardieu, A. Togias, and J. McKenzie-White Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody J Immunol 158 1997 1438 1445 (Pubitemid 127469971)
9. G. Gomez, S. Jogie-Brahim, M. Shima, and L.B. Schwartz Omalizumab reverses the phenotypic and functional effects of IgE-enhanced FcepsilonRI on human skin mast cells J Immunol 179 2007 1353 1361